Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model

British Journal of Ophthalmology

Volumn 89, Issue 4, 2005, Pages 504-507

  Seki, M ^a   Tanaka, T ^a   Matsuda, H ^a   Togano, T ^a   Hashimoto, K ^a   Ueda, J ^a   Fukuchi, Takeo ^a   Abe, H ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; INDIAN INK; MYTEAR; TIMOLOL; TIMOLOL XE; ANTIHYPERTENSIVE AGENT; EYE DROPS; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROTECTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; EXPERIMENTAL MODEL; GLAUCOMA; HISTOPATHOLOGY; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; NERVE CELL NECROSIS; NONHUMAN; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RAT; RAT STRAIN; RETINA GANGLION CELL; TISSUE SECTION; ANIMAL; CELL SURVIVAL; DISEASE MODEL; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL COUNT; CELL SURVIVAL; CYTOPROTECTION; DISEASE MODELS, ANIMAL; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 16244362673     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.052860     Document Type: Article

References (20)

1. Quigley HA. Neuronal death in glaucoma. Prog Refin Eye Res 1999;18:39-57.
2. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol 2003;48(Suppl 1):S3-7.
3. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126:487-97.
4. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126:498-505.
5. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:429-40.
6. Levin LA. Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 2003;48(Suppl 1):S21-4.
7. Ueda J, Sawaguchi S, Hanyu T, et al. Experimental glaucoma model in the rat induced by laser trabecular photocoagulation after an intracameral injection of India ink. Jpn J Ophthalmol 1998;42:337-44.
8. Moore CG, Milne ST, Morrison JC. Noninvasive measurement of rat intraocular pressure with the Tono-Pen. Invest Ophthalmol Vis Sci 1993;34:363-69.
9. Goto W, Ota T, Morikawa N, et al. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res 2002;958:10-19.
10. Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003;44:1982-92.
11. Schuettauf F, Quinto K, Naskar R, et al. Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vis Res 2002;42:2333-37.
12. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-5.
13. Messmer C, Flammer J, Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 1991;112:678-81.
14. Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol 1994;38(Suppl):S149-55.
15. Wood JP, Schmidt KG, Melena J, et al. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res 2003;76:505-16.
16. Johnson JE, Barde YA, Schwab M, et al. Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J Neurosci 1986;6:3031-38.
17. Mansour-Robaey S, Clarke DB, Wang YC, et al. Effects of ocular injury and administration or brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci USA 1994;91:1632-6.
18. Wood JP, DeSantis L, Chao HM, et al. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp Eye Res 2001;72:79-86.
19. Ko ML, Hu DN, Ritch R, et al. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci 2000;41:2967-71.
20. Seki M, Nawa H, Fukuchi T, et al. BDNF is upregulated by postnatal development and visual experience: quantitative and immunohistochemical analyses of BDNF in the rat retina. Invest Ophthalmol Vis Sci 2003;44:3211-18.